hims glp-1 news Affordability and Safety: How & Hers is Delivering a New Experience Through the Scale of Our Platform Hims & Hers launches into

Key Results Semaglutide vs Sitagliptin HR 0.58 (95% CI, 0.510.65) 42% lower risk 1-yr absolute risk: 5.5% vs 8.6% NNT 31 Tirzepatide vs Sitagliptin HR 0.42 (95% CI, 0.310.57) 58% lower risk 1-yr absolute risk: 3.6% vs 7.5% NNT 26 Tirzepatide vs Semaglutide HR 0.86 (95% CI, 0.701.06) no statistically significant difference Safety: No excess signal for GI, infections, or serious AEs across GLP-1/dual arms

however, the study suggests that children under 12 may also benefit from their use

Additionally, short study durations and standardized laboratory conditions restrict conclusions regarding long-term endocrine adaptation or translational applicability

The BOP decided this could only be done by compounding pharmacies while also taking actions that serve to drive compounding pharmacies out of the state